Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16322879 | 0.88 | — | — | |
| SCHEMBL16010264 | 0.83 | SIRT3 (0.30) | — | |
| SCHEMBL17112797 | 0.82 | GAA (0.33) | — | |
| SCHEMBL16762112 | 0.81 | CA12 (0.36) | GPR119 | |
| SCHEMBL18839479 | 0.79 | SSTR4 (0.33) | — | |
| SCHEMBL4353461 | 0.79 | GAA (0.30) | — | |
| SCHEMBL17099864 | 0.78 | LATS1 (0.33) | GPR119 | |
| SCHEMBL15484154 | 0.78 | CA12 (0.39) | — | |
| SCHEMBL15051595 | 0.75 | KMT2A (0.34) | GPR119 | |
| SCHEMBL1806496 | 0.75 | CES2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025060978-A1 | TRICYCLIC PYRIDINE COMPOUND ACTING AS SARM1 ENZYME ACTIVITY INHIBITOR, AND USE THEREOF | 科辉智药(深圳)新药研究中心有限公司 | 2025-03-27 | — | — | WO | disclosed |
| WO-2022180150-A1 | IMIDAZO[1,2-A]PYRAZINES AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-09-01 | — | — | WO | disclosed |
| EP-4049726-A1 | IMIDAZO[1,2-A]PYRAZINES AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-08-31 | — | — | EP | disclosed |
| EP-3581570-B1 | CARBAZOLE-PYRIDINE-TRIFLUOROMETHYLPHENYL DERIVATIVES AND RELATED COMPOUNDS FOR USE AS TADF LUMINESCENT EMITTERS IN OLEDS | CYNORA GMBH (DE) | 2021-04-21 | — | — | EP | disclosed |
| EP-3575377-B1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-03-17 | — | — | EP | disclosed |
| CN-107406426-B | Cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2020-11-20 | — | — | CN | disclosed |
| EP-3242873-B1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3575377-A1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-12-04 | — | — | EP | disclosed |
| US-10385065-B2 | Antibacterial compounds | REDX PHARMA PLC (GB) | 2019-08-20 | — | — | US | disclosed |
| US-10280170-B2 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-07 | — | — | US | disclosed |
| EP-3129386-A1 | ANTIBACTERIAL COMPOUNDS | Redx Pharma PLC (GB) | 2017-02-15 | — | — | EP | disclosed |
| WO-2016144936-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016112236-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | WO | disclosed |
| WO-2015155549-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2015-10-15 | — | — | WO | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1966151-B1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORP (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| EP-1966151-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | GPR119 1217/4885LOXL2 3105/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | GPR119 1990/4885LOXL2 3282/4885 |
| US-10280170-B2 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors | ROS1, NOX1, NOX5 | GPR119 2103/4885LOXL2 2219/4885 |
| US-10385065-B2 | Antibacterial compounds | ABCC1, SLC11A2, NQO2 | GPR119 4254/4885LOXL2 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.